Pancreatic Cancer Research

ResearcherAichi Cancer CenterActive in the last 2 years

Kazuo Hara

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4699-6136; OpenAlex author ID A5048078824, A5121111324. Sources: OpenAlex.

Their work

Papers
26 (first author 4, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
101
Papers, trials and grants by year

2011: 3 papers · 2012: none · 2013: 2 papers · 2014: none · 2015: none · 2016: 5 papers · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 4 papers

Papers 26

  1. Establishment of simple pancreatic ductal adenocarcinoma identification method: S100P measurement in duodenal fluid obtained during upper gastrointestinal endo… Co-author DOI 10.1016/j.pan.2025.12.020↗
  2. Phase 1 trial of lavage cytology collected with endoscopic ultrasound-guided fine-needle aspiration for preoperative pancreatic cancer. First author DOI 10.1055/a-2781-5703↗
  3. KRAS Mutations in Duodenal Lavage Fluid After Secretin Stimulation for Detection of Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006645↗
  4. Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II t… Co-author DOI 10.1186/s12885-026-15699-8↗
  5. [Precision medicine in pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.122.834↗
  6. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  7. Clinical impact of intraoperative pancreatic transection margin analysis and additional resection during pancreaticoduodenectomy for pancreatic ductal adenocar… Co-author DOI 10.1016/j.pan.2024.10.003↗
  8. Clinical utility of endoscopic ultrasound-guided tissue acquisition for comprehensive genomic profiling of pancreatic cancer. First author DOI 10.5946/ce.2022.086↗
  9. Prognostic Significance of Intraoperative Peritoneal Lavage Cytology in Patients with Pancreatic Ductal Adenocarcinoma: A Single-Center Experience and Systemat… Co-author DOI 10.1245/s10434-022-11722-x↗
  10. Survival benefit of surgery for very elderly patients with pancreatic cancer: what extent of pancreatectomy is acceptable? Last author DOI 10.18999/nagjms.83.2.239↗
  11. Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer. Co-author DOI 10.1038/s41467-020-16711-w↗
  12. A novel sensitive detection method for DNA methylation in circulating free DNA of pancreatic cancer. First author DOI 10.1371/journal.pone.0233782↗
  13. Conversion surgery only for highly selected patients with unresectable pancreatic cancer: a satisfactory outcome in exchange for a lower resection rate. Last author DOI 10.1007/s00595-019-01776-y↗
  14. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combi… Co-author DOI 10.1186/s13063-019-3332-5↗
  15. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. Co-author DOI 10.1002/ijc.31047↗
  16. Prediction model for pancreatic cancer risk in the general Japanese population. Co-author DOI 10.1371/journal.pone.0203386↗
  17. Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis … Co-author DOI 10.1016/j.ejca.2015.11.002↗
  18. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study. Co-author DOI 10.1016/j.pan.2016.04.007↗
  19. Prognostic impact of carcinoembryonic antigen (CEA) on patients with metastatic pancreatic cancer: A retrospective cohort study. Co-author DOI 10.1016/j.pan.2016.05.007↗
  20. Evaluation of Modified Glasgow Prognostic Score for Pancreatic Cancer: A Retrospective Cohort Study. Co-author DOI 10.1097/mpa.0000000000000446↗
  21. Clinical impact of preoperative endoscopic ultrasound-guided fine-needle aspiration for pancreatic ductal adenocarcinoma. Co-author DOI 10.4103/2303-9027.180472↗
  22. Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancrea… Co-author DOI 10.1007/s00535-012-0664-2↗
  23. Cytoplasmic expression of LGR5 in pancreatic adenocarcinoma. Co-author DOI 10.3389/fphys.2013.00269↗
  24. Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer. Co-author DOI 10.1007/s00280-010-1531-6↗
  25. Current concept of endoscopic ultrasound-guided fine needle aspiration for pancreatic cancer. First author DOI 10.1159/000323502↗
  26. Interventional endoscopic ultrasonography for pancreatic cancer. Co-author DOI 10.5306/wjco.v2.i2.108↗

Closest collaborators

The 25 strongest of 101 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shin Haba · 4 shared papers, 2023–2026 · strength 1.09
  2. Nozomi Okuno · 4 shared papers, 2016–2026 · strength 0.94
  3. Susumu Hijioka · 10 shared papers, 2011–2026 · strength 0.66
  4. Seiji Natsume · 5 shared papers, 2016–2024 · strength 0.60
  5. Nobumasa Mizuno · 9 shared papers, 2011–2023 · strength 0.55
  6. Masayuki Kitano · 3 shared papers, 2019–2026 · strength 0.52
  7. Keitaro Matsuo · 5 shared papers, 2018–2022 · strength 0.50
  8. Kenji Yamao · 9 shared papers, 2011–2020 · strength 0.45
  9. Keiji Hanada · 2 shared papers, 2026 · strength 0.44
  10. Taro Yamashita · 2 shared papers, 2026 · strength 0.41
  11. Kazuyoshi Ohkawa · 2 shared papers, 2026 · strength 0.41
  12. Waki Hosoda · 3 shared papers, 2013–2024 · strength 0.35
  13. Makoto Ueno · 3 shared papers, 2018–2026 · strength 0.33
  14. Hiroshi Imaoka · 7 shared papers, 2013–2016 · strength 0.33
  15. Kentaro Sudo · 2 shared papers, 2019–2026 · strength 0.31
  16. Akio Katanuma · 2 shared papers, 2019–2026 · strength 0.31
  17. Tatsuya Ioka · 2 shared papers, 2019–2026 · strength 0.27
  18. Saki Yamazoe · 1 shared paper, 2026 · strength 0.27
  19. Satoshi Kobayashi · 2 shared papers, 2018–2026 · strength 0.26
  20. Masato Ozaka · 2 shared papers, 2018–2026 · strength 0.26
  21. Naoki Sasahira · 2 shared papers, 2018–2026 · strength 0.26
  22. Masafumi Nakamura · 1 shared paper, 2026 · strength 0.24
  23. Mamoru Takenaka · 1 shared paper, 2026 · strength 0.24
  24. Shinichi Hashimoto · 1 shared paper, 2026 · strength 0.24
  25. Noboru Ideno · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.